Hyperinsulinemia and Cancer Risk: A Potential Link Highlighted.

A recent article published in the Journal of Clinical Endocrinology & Metabolism discusses the potential role of hyperinsulinemia — a condition of chronically elevated insulin levels — in the development and progression of cancer.Key observationsHyperinsulinemia is associated with increased cancer incidence and mortality, raising concerns beyond its metabolic effects.

Restoring the Infant Mortality Rate as a Measure of Societal Health

The infant mortality rate (IMR) — deaths in the first year of life per 1000 live births — has long been considered a central measure of public health. A recent New England Journal of Medicine article by Harrison, Ndulue, and Ojikutu revisits the IMR’s role as an indicator of societal well-being and equity.Historical contextAt the end of the 19th century, IMR disparities in B

Extending Aromatase Inhibitor Therapy Reduces Recurrence in HR+ Breast Cancer

A new large-scale meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), published in The Lancet (August 2025), evaluated the impact of extending adjuvant aromatase inhibitor therapy (AIT) in postmenopausal women with hormone receptor-positive (HR+) early breast cancer. Key findingsPopulation: 24,

Menopause Symptoms and Treatment Approaches: Hormonal and Nonhormonal Options

Menopause, defined as the loss of ovarian follicular activity without another pathological or physiological cause, generally occurs between 45 and 56 years of age. During this transition, 50% to 75% of women experience vasomotor symptoms (hot flashes and night sweats), and more than 50% develop genitourinary syndrome of menopause (GSM), both of which significantly affect quality of life. Vasomotor symptoms often persist for more than 7 years, while GSM is typically ch

Presymptomatic risdiplam in SMA: early treatment linked to major motor milestones.

In an editorial accompanying the phase 2 trial by Finkel et al., Sumner reviews presymptomatic use of risdiplam—an oral SMN2 pre‑mRNA splicing modifier—for spinal muscular atrophy (SMA). Risdiplam binds SMN2 transcripts at intron 7 and exon 7, stabilizing exon 7 inclusion and increasing production of full‑length SMN protein, with broad tissue biodistribution and blood–brain barrier penetration.The study enrolled 26 infants identified la

ESMO Consensus Recommendations for Cardio-Oncology in Cancer Care.

The European Society for Medical Oncology (ESMO) has released a comprehensive consensus statement on the prevention, diagnosis, and management of cardiovascular disease (CVD) in patients undergoing cancer therapy. The guidelines emphasize the importance of integrating cardio-oncology into routine oncologic practice to address the growing burden of treatment-related cardiotoxicity.The document highlights that baseline cardiovascular risk

Cardiovascular Toxicity in Cancer Survivors: Persistent Risks and Emerging Strategies.

Cancer survivorship has increased significantly over recent decades due to advances in early detection and treatment. However, this success has brought a parallel rise in cardiovascular disease (CVD) as a major cause of morbidity and mortality among survivors. Both cancer and CVD share risk factors such as age, smoking, obesity, and metabolic syndrome, but oncologic therapies—including anthracyclines, HER2-targeted agents, vascular endothelial growth factor inhibitors

Discovery of FVIII “Aurora” Mutation Opens New Perspectives for Hemophilia A Therapy.

Researchers from the University of Colorado have identified a naturally occurring gain-of-function mutation in factor VIII (FVIII), designated Arg590Ser and named “FVIII Aurora,” in an 18-year-old male with a history of recurrent, life-threatening thromboses since birth. Laboratory evaluation revealed markedly elevated clotting FVIII activity (300–900% of normal) with normal FVIII antigen and chromogenic activity, alongside increased thrombin generation velocity and r

Advances and Ongoing Challenges in Rare Endocrine Disorders.

Rare endocrine disorders encompass a broad spectrum of conditions, including congenital adrenal hyperplasia, hypophosphatasia, X-linked hypophosphatemia, rare thyroid carcinomas, and hereditary syndromes such as multiple endocrine neoplasia. While individually uncommon, collectively they represent a significant clinical and societal burden, often marked by delayed diagnosis, limited therapeutic options, and complex multisystem involvement.

Rare Diseases